INTRODUCTION
T ransurethral resection of the prostate (TURP) is widely accepted as the gold standard in surgical treatment of benign prostatic obstruction (BPO) due to benign prostatic hyperplasia (BPH) and has passed the test of the time [1] [2] [3] [4] . Nevertheless, the procedure is limited by prostate volume and is indicated for small and medium sized prostates 5, 6 . Beside that, it is still challenging related to considerable complications, which encompass bleeding, TUR syndrome and acute myocardial infarction 3, 7, 8 . The procedure has morbidity rate 15%-20% and retreatment rate 3%-14.5% 3, 5 .
The relatively high complication rates following TURp have led to the appearance of less invasive procedures. During the last 20 years, numerous of minimal invasive treatments for BPH, including laser techniques, have been described [9] [10] [11] [12] [13] [14] . Holmium laser enucleation of the prostate (HoLEP), initially introduced by Peter Gilling in 1996, has been entirely recognized now as a great potential alternative technique 9, 10, 15 . Physical characteristics of holmium laser beam enable excellent effects in prostate tissue cutting and haemostasis through the saline 16 . Several short-term and long-term studies performed on HoLEP had confirmed high efficacy and safety profile of the procedure. Comparative trials in regard with TURp have demonstrated significant reduction of perioperative morbidity and functional results comparable to TURp 9, 10, 16, 19, [21] [22] [23] . The procedure is less invasive than TURp, with minimal risk of perioperative bleeding and TUR syndrome 17, 20, 24, 25 . Furthermore, with HoLEP we can treat any prostate size without limitation 16, 26, 27 . The procedure has been completed by a special device-soft tissue morcellator, which allows the exteriorization of whole lobes of prostate for histological examination 16 . However, the procedure requires a greater length of training. 
AIM

MATERIALS AND METHODS
Between October 2011and December 2012, 40 consecutive patients presenting with lower urinary tract symptoms secondary to benign prostatic hyperplasia, with prostate volume <50g, categorized as "non-responders" to pharmacologic therapy, were considered suitable for minimally invasive surgical treatment and included into the prospective study. Patients were randomized to holmium laser enucleation of the prostate -HoLEP group (20 cases; mean age 63,3+7,4 years old) or transurethral resection of the prostate-TURp group (20 cases; mean age 65,1+6,9 years old). Inclusion criteria were: postvoid residue = 50ml, prostate volume up to 50g, repeated episodes of acute urinary retention, indwelling urinary catheter, recurrent urinary tract infection, recurrent haematuria due to BPH and IPSS score >19. Exclusion criteria were voiding disorders out of BPH origin, previous urethral, bladder neck or prostatic surgery, and history of prostate cancer. All patients have been evaluated by medical history, digital rectal exam (DRE), complete blood count and serum biochemistry, prostate specific antigen (PSA), urine analysis and urine culture, urinary tract ultrasound with postvoid residual urine, International Prostate Symptom Score (IPSS) and single question quality of life score (QoL). In order to exclude prostate cancer, patients with positive DRE or elevated PSA level (=4ng/ml) underwent transrectal prostatic biopsy. The HoLEP was performed by 2J/50Hz, 100-watt holmium laser device (VersaPulse® PowerSuite, Lumenis, Yokneam, Israel), using a 550-•m endfiring fiber (SlimLineTM 550, Lumenis Inc.). Transurethral resection of the prostate was performed using the standardized tungsten wire loop (Richard Wolf, Knittlingen, Germany) with a 160W cutting and 80W coagulating current.The operative technique for HoLEP was performed as described by Gilling et al 15 . It involves 5-and 7-o'clock incisions, with retrograde anatomic enucleation of the median lobe, and afterwards left and right lateral lobe. During the enucleation, special attention is given to find and maintaining of the surgical plane between the peripheral zone of the prostate and the capsule as well as to perform adequate hemostasis. After the completion of the enucleation, the lobes have been moved into the bladder. In few cases (n=3), the HoLEP was combined with TURp. Using tissue morcellator the lobes have been fragmented and exteriorized. Subsequently, the obtained specimens were weighed and sent for histological examination. After the exteriorization of fragmented prostatic tissue, an 3-way irrigating operative catheter was inserted. Bladder irrigation was performed as intermittent or continuous, depending on the degree of hematuria. The catheter was removed on the first postoperative day. All HoLEP procedures have been performed by two trained urologists.
Perioperative data included operating time (including morcelation time for the HoLEP group), weight of resected tissue, drop in serum sodium and hemoglobin concentrations, catheter removal time, hospitalization time and morbidity. All data, including subsequent pathohistological findings were collected in a database. All patients have been evaluated during the postoperative follow-up period at the 1-, 3-, 6-, and 12 th month. The follow-up protocol included data of voiding symptoms (urgency, frequency, nocturia, urinary incontinence and hematuria), International Prostate Symptom Score (IPSS) and Single Question Quality of Life Score (QoL) questionnaires and urinary tract ultrasound with postvoid residual urine. Complete blood count and serum biochemistry, urine analysis and urine culture were evaluated after the 1st month postoperatively, and reevaluated if it was indicated. All data have been recorded and were compared before surgery and after, as well as between the analyzed groups.
Mean, SD and student's t-test were used as well as nonparametric tests for analyzing the data obtained from the two groups.
RESULTS
Regarding baseline characteristics, there were no significant differences between the analyzed groups (HoLEP group vs TURp group) (table 1). All patients reached the 12-month follow-up.
Operative time was significantly longer in HoLEP group. There was no difference regarding prostatic tissue specimen weight, while hemoglobin levels drop, catheterisation time and the length of hospitalization had been statistically significant higher in the TURp group. Only two patients from the TURp group required blood transfusion. Intraoperative and perioperative data are presented in Table 2. A total of 16 patients, 3 from the HoLEP group and 13 from the TURp group, had some of late complications. It was fewer in the TURp group (p<0,01). Dysuria was the most common complication, especially in the TURp group (p<0,05). The frequency of urge incontinence and bladder neck stricture didn't show significant differences between the analyzed groups. There was no need for reintervention for bleeding due to late complications. Table 3 shows early and late postoperative complications.
Postoperative follow-up data regarding International Prostate Symptom Score (IPSS) demonstrated significant differences in favor of the HoLEP group, both at 6-month (p<0,05) and 12-month (p<0,01), as well as Single Question Quality of Life Score (QoL), which had also indicated the superiority of the results in the HoLEP group, at 6-month (p<0,01) and 12-month (p<0,05). Postvoid residual urine (PVR) was statistically significant lower in the HoLEP group at 6-month (p<0,01). Follow-up data regarding IPSS, QoL and PVR are summarized in Table 4 .
DISCUSSION
Since 1994, high-powered holmium lasers have been introduced into the clinical practice. New technological advances had improved laser performances in various modalities, including vaporization, ablation, resection, incision and enucleation. 5, 9 Numerous of so-called minimally invasive procedures have been proposed as alternatives to TURp. However, most of them have not achieved TURp regarding efficacy and durability 16 . Holmium laser enucleation of the prostate (HoLEP) was introduced as a technological improvement of holmium laser resection of the prostate (HoLRP), to overcome the drawbacks regarding the efficacy of prostatic tissue removal 28 . It was initially recognized as an TURp alternative for small and mediumsized prostates, since its excellent performances regarding hemostasis. The invention of new device-transurethral mechanical tissue morcellator, made it possible to perform entire lobe enucleation, removal into the bladder, and finally, fragmentation and exteriorization of the prostatic tissue 5, 9, 29 . Hence, it was possible to perform the enucleation of high volume prostates, too. Recent studies have demonstrated feasibility and safety of the procedure even for prostate glands >300g 10, 15, 17, 18, 24, 26, 27, [30] [31] [32] [33] [34] . Therefore, HoLEP has became alternative treatment, not only to TURp, but also to open prostatectomy 18, 26 . Since the HoLEP has shown excellent haemostatic properties, numerous studies regarding its feasibility, safety and efficacy, had been conducted. Our study results show the superiority of HoLEP with regard to hemoglobin level drop, catheterisation time and the length of hospitalization. No HoLEP patients required blood transfusions in contrast to two transfusions in the TURP group. The prostatic tissue specimen weight was similar in both groups. However, the operative time was significantly longer in the HoLEP group. In large series analysis, Kunz reported mean catheterisation time of 1-2 days, mean hospital stay of 2-3 days, and low rates of blood loss and recatheterisation 5 . Consistent findings are reported by other authors 35 . Wilson et al 16 in prospective randomized study demonstrated similar results regarding catheterisation time and the length of hospitalization. However, in this study, the prostatic tissue specimen obtained by HoLEP was higher versus TURp, since the range of perioperative volume of the prostate was up to 200g. Since our initial experiences with the HoLEP in our study, the prostate volume was limited to 50g. Tan et colleagues performed the meta analysis comparing HoLEP and TURp 25 . Pooled data from this study indicate significant advantages of HoLEP to TURp, in terms of catheterisation time, hospital stay, and blood loss, which have been reconfirmed with results reported by Laurenco et al 29 . The results of another randomized clinical trial indicate the superiority of HoLEP related to blood loss and blood transfusions 9 . Additionally, HoLEP is prostate volume size-independent, regarding catheter time, hospital stay, blood transfusion rate, complication rate, and micturition outcome, as reported by Kunz et al. in a large prospective study 5, 23 . In contrast, the outcome of TURp directly correlates with prostate gland size in respect of complications including blood loss 5, 7 . Otherwise, the HoLEP group have demonstrated more favorable results with both early and late postoperative complications, especially with respect to dysuria and transient incontinence. There were no cases that required reintervention for bleeding or cases with stress urinary incontinence in both groups. Only one patient from the TURp group had and bladder mucosal injury. Acute urinary retention appeared in one patient from the HoLEP group and two from the TURp group. There were only few late complications, including bladder neck stricture in one patient from the TURp group and urge incontinence in three patients (two from the TURp and one from the HoLEP group). Low rate of perioperative morbidity following HoLEP has been confirmed by numerous short-term and long-term studies 36 . Comparing HoLEP to TURp, Gilling and co-workers reported minimal perioperative morbidity and superiority of HoLEP for smaller glands 16, 17, 23, 36 . The pooled data of large series revealed low postoperative complication rates in respect to reintervention for bleeding, urethral stricture, bladder neck contracture and urinary tract infections 5 . In respect of International Prostate Symptom Score (IPSS), Single Question Quality of Life Score (QoL) and postvoid residual urine (PVR), the results in the HoLEP group are superior to the TURp group, both at 6-month and 12-month follow-up. Recently published data from several large case series, clearly indicate marked improvements of IPSS/AUA symptom scores, peak flow rates and postvoid residual urine, with significant reduction of prostate volume, between 62% and 77% 18, 24, 27, [37] [38] [39] . Ahyai et al., reported advantageous short follow-up results of HoLEP vs TURp, in term of bladder neck desobstruction, claiming that it is the unique endourologic technique that could obtain better micturition outcomes than TURp with lasting improvement 9 . Similar findings were presented by Tan and co- . In meta analysis comparing HoLEP and TURp, Gilling and co-workers found better urodynamic parameters following HoLEP procedure, for prostates >50g and had emphasized that it is the first endourologic procedure that could achieve better bladder outlet desobstruction than TURp 10 . Better improvement of micturition obtained by HoLEP vs TURp has been also verified by several randomized studies 5, 10, 17, 20, 23, 25 .
CONCLUSIONS
HoLEP is minimally invasive technique that gives excellent operative results in terms of safety and efficacy. After one-year follow-up, it demonstrated superiority to TURp in regards to perioperative and follow-up data. Although HoLEP was initially described as an TURp alternative, it has a great potential to become a "volume-independent", new gold standard in the surgical treatment of BPH.
SUMMARY HOLIJUM LASERSKA ENUKLEACIJA PROSTATE VR TRANSURETRALNA RESEKCIJA: POREDJENJE REZULTATA
Holmijum laserska enukleacija prostate (HoLEP) predstavlja alternativnu tehniku velikih mogu}nosti u odnosu na standardnu transuretralnu resekciju prostate (TURP). Prezentujemo rezultate randomizovane klini~ke studije koja uporedjuje HoLEP i TURp, sa vremenom pra}enja 12 meseci.
Ukupno 40 pacijenata sa BPH i volumenom prostate < 50g, randomizovano je za HoLEP (n=20) ili TURp (n=20). Ultrazvuk urinarnog trakta sa postmikcionim rezidualnim urinom (PVR), Internacionalni prostate symptom skor (IPSS) i "single question" skor kvaliteta 'ivota, evaluirani su preoperativno i tokom perioda pra}enja, 1,3,6 i 12. postoperativnog meseca. Procenjivani su intra i perioperativni podaci kao i rane i kasne komplikacije.
Operativno vreme bilo je du'e u HoLEP grupi (p<0,001); vreme kateterizacije (p<0,05) i boravka u bolnici (p<0,05) kra}e; pad nivoa hemoglobina (p<0,001) bio je viši u TURp grupi. Rane i kasne postoperativne komplikacije bile su ~eš}e u TURp grupi (p<0,001). Podaci iz postoperativnog pra}enja bili su bolji u HoLEP grupi, i pogledu IPSS posle 6 meseci (p<0,05) i posle 12 meseci (p<0,01), i u pogledu QoL skora, posle 6 meseci (p<0,01) i posle 12 meseci (p<0,05). PVR je bio ni'i u HoLEP grupi posle 6 meseci (p<0,01).
HoLEP pokazuje superiornost u odnosu na TURp u pogledu perioperativnih parametara i podataka iz perioda pra}enja i ima veliki potencijal da postane novi "zlatni standard" u hirurškom le~enju BPH.
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